Cerevel Therapeutics Holdings (CERE) Prices 14M Share Offering at $25/sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/27/2026
- Nasdaq futures outperform after Nvidia puts AI fears to rest
- Nvidia forecasts 70% sales growth next year, signals AI spending boom has years left to run
- Oil gains as traders weigh prospects of easing Middle East supply disruptions
- Meta to pay up to $16.68 billion in mass social media settlement
- Anthropic agrees to $45bn cloud computing deal with Nscale - report
- Nutanix (NTNX) Tops Q4 EPS by 11c, Beats in Revenue; Offers Q1 Revenue Guidance
- Boston Scientific discloses cybersecurity incident causing global disruption
- Crude Inventory Rose 0.1 Million Barrels Last Week - EIA
- Wall Street stocks end tad lower after hot inflation data ahead of Nvidia earnings
- FDA approves Revolution Medicines pancreatic cancer drug Rasonque
Cerevel Therapeutics Holdings (CERE) Cerevel Therapeutics Holdings (NASDAQ: CERE) 30-day option implied volatility at 143 on more puts than calls
July 2, 2021 4:42 AM EDTCerevel Therapeutics Holdings (NASDAQ: CERE) 30-day option implied volatility is at 143; compared to its 52-week range of 83 to 345. Call put ratio 1 call to 2 puts.
... MoreCerevel Therapeutics Holdings (CERE) call put ratio 1 call to 2 puts after sharp rally
July 1, 2021 3:55 PM EDTCerevel Therapeutics Holdings (NASDAQ: CERE) 30-day option implied volatility is at 140; compared to its 52-week range of 83 to 345. Call put ratio 1 call to 2 puts.
... MorePre-Open Stock Movers 06/30: (OCUP) (ASTS) (XELA) Higher; (ALT) (ECOR) (REPX) Lower (more...)
June 30, 2021 9:27 AM EDTPre-Open Stock Movers:
Ocuphire Pharma, Inc. (Nasdaq: OCUP) 40.6% HIGHER; announced that the VEGA-1 Phase 2 clinical trial evaluating the efficacy and safety of Nyxol in combination with low-dose pilocarpine (LDP) in presbyopic subjects successfully met its primary and many secondary endpoints. On the strength of these results, Ocuphire plans to move into Phase 3. Given the rapid onset and sustained duration of efficacy, the favorable safety profile, and the potential tunability of... More
Cerevel Therapeutics (CERE) PT Raised to $30 at Goldman Sachs
June 30, 2021 9:13 AM EDTGoldman Sachs analyst Graig Suvannavejh raised the price target on Cerevel Therapeutics (NASDAQ: CERE) to $30.00 (from $23.00) while maintaining a Buy rating.... More
